Pliant Therapeutics, Inc.
PLRX
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of av6 and av1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecuā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.04
Price-1.89%
-$0.02
1Y
Price
Market Cap
$64.397m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-33.3%
3y CAGR-45.9%
5y CAGREarnings
-$113.218m
+24.2%
1y CAGR+7.6%
3y CAGR-2.0%
5y CAGREPS
-$1.84
+24.3%
1y CAGR+9.4%
3y CAGR+8.6%
5y CAGRBook Value
$165.166m
$202.596m
Assets$37.430m
Liabilities$28.784m
DebtDebt to Assets
14.2%
-0.3x
Debt to EBITDAFree Cash Flow
-$98.813m
+23.2%
1y CAGR+2.2%
3y CAGR-3.8%
5y CAGRNo items found.
Press Releases
Statements and updates from the company